New immune cell therapy for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new treatment using your own immune cells (called neutrophils) that are loaded with a drug to fight pancreatic cancer that cannot be removed by surgery. It may be an option if standard treatments have stopped working or caused bad side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have pancreatic cancer that cannot be removed by surgery, confirmed by a tissue sample (biopsy).
- Standard first-line treatments have not worked or caused severe side effects, or you choose not to have them and want to try this new therapy.
- You are generally able to care for yourself (ECOG score 0–2) and your doctor expects you to live at least 3 more months.
- Your liver, kidney, and bone marrow function are close to normal based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
This trial tests an experimental cell therapy called MT-601 for people with advanced pancreatic cancer that has not worsened during standard chemotherapy (FOLFIRINOX or nab-paclitaxel/gemcitabine). The goal is to see if this new treatment can help control the cancer.
This trial tests a personalized mRNA vaccine made from your own tumor's unique markers (neoantigens). It is for people with advanced pancreatic cancer that has spread or come back, and who have had limited or no prior chemotherapy. The goal is to see if this vaccine can help the immune system fight the cancer.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This trial tests a new drug called mitazalimab injected directly into the tumor, combined with a special electrical procedure that kills cancer cells. It is for people whose pancreatic cancer has not spread but cannot be removed by surgery.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
Hear when a new Unresectable Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.